#1 Clinical Trials Search in Europe

Ravulizumab

Ravulizumab, also known as ALXN1210 or Ultomiris, is a monoclonal antibody being studied in clinical trials for various conditions. These trials aim to evaluate its safety, efficacy, and pharmacological properties in treating diseases such as neuromyelitis optica spectrum disorder (NMOSD), paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and COVID-19-related complications. The drug works by inhibiting the complement system, a part of the immune system, and is administered intravenously or subcutaneously.

Table of Contents

What is Ravulizumab?

Ravulizumab, also known by its brand name Ultomiris or research name ALXN1210, is a medication used to treat several rare blood and neurological disorders[1][2]. It is a type of drug called a monoclonal antibody, which means it’s a laboratory-made protein that mimics the immune system’s ability to fight off harmful antigens such as viruses[4].

What Conditions Does Ravulizumab Treat?

Ravulizumab is approved to treat several conditions:

  • Paroxysmal Nocturnal Hemoglobinuria (PNH): This is a rare blood disorder where red blood cells break down earlier than they should[2].
  • Atypical Hemolytic Uremic Syndrome (aHUS): This is a rare condition that causes abnormal blood clots to form in small blood vessels in the kidneys[4].
  • Neuromyelitis Optica Spectrum Disorder (NMOSD): This is a rare neurological condition that affects the optic nerves and spinal cord[1].
  • Generalized Myasthenia Gravis (gMG): This is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles[5].

How Does Ravulizumab Work?

Ravulizumab works by targeting a specific part of the body’s immune system called the complement system. Specifically, it blocks a protein called C5, which is part of the complement system. In the conditions that ravulizumab treats, the complement system is overactive and causes damage to the body’s own cells[3].

By blocking C5, ravulizumab helps to prevent this damage. It causes immediate and sustained inhibition of the terminal complement cascade, which is the part of the complement system that causes the most damage in these conditions[4].

How is Ravulizumab Administered?

Ravulizumab is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The dosing schedule depends on your weight and the specific condition being treated[1]:

  • You’ll usually receive a loading dose on the first day of treatment.
  • After that, you’ll receive maintenance doses every 4 or 8 weeks, depending on your weight.
  • The infusion typically takes several hours to complete.

Researchers are also studying a subcutaneous (under the skin) version of ravulizumab, which could potentially be more convenient for some patients[3].

Efficacy of Ravulizumab

Clinical trials have shown that ravulizumab is effective in treating the conditions it’s approved for. Here are some key findings:

  • In PNH, ravulizumab has been shown to reduce the need for blood transfusions and improve symptoms like fatigue[2].
  • In NMOSD, it helps prevent relapses (flare-ups of symptoms) and may slow the progression of disability[1].
  • In gMG, it improves muscle strength and daily functioning[5].

Safety and Side Effects

Like all medications, ravulizumab can cause side effects. Common side effects may include[6]:

  • Headache
  • Upper respiratory tract infections
  • Diarrhea
  • Nausea
  • Fever

More serious side effects are possible but less common. These can include serious infections, as ravulizumab affects part of your immune system. Your doctor will monitor you closely for any signs of infection[6].

Ongoing Research

Researchers continue to study ravulizumab to better understand its effects and explore its potential in treating other conditions. Some areas of ongoing research include:

  • Its use in treating children with NMOSD[1].
  • Its effectiveness in Chinese adults with PNH[2].
  • Its potential in treating COVID-19-related complications[4].
  • The development of a subcutaneous version for easier administration[3].
  • Its long-term effects on brain and spinal cord imaging in people with NMOSD[7].

These ongoing studies help doctors and researchers better understand how to use ravulizumab effectively and safely, and may lead to its approval for treating additional conditions in the future.

Aspect Details
Drug Name Ravulizumab (also known as ALXN1210, Ultomiris)
Drug Type Monoclonal antibody targeting complement protein C5
Administration Intravenous (IV) infusion, some studies exploring subcutaneous (SC) injection
Conditions Studied NMOSD, PNH, gMG, COVID-19 complications
Patient Populations Adults and pediatric patients (in some trials)
Primary Outcomes Safety, efficacy, pharmacokinetics, pharmacodynamics
Secondary Outcomes Disease-specific scores, quality of life measures, biomarker levels
Study Designs Phase 1-3 trials, open-label, single-arm, and randomized controlled studies
Duration Varies by study, ranging from single-dose to multiple years of treatment

FAQ

  • What conditions is Ravulizumab being studied for in clinical trials? Ravulizumab is being studied for several conditions, including neuromyelitis optica spectrum disorder (NMOSD), paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and COVID-19-related complications such as thrombotic microangiopathy and acute kidney injury.
  • How is Ravulizumab administered in clinical trials? In clinical trials, Ravulizumab is typically administered intravenously (IV). Some studies are also exploring subcutaneous (SC) administration. The dosing is usually weight-based and follows a schedule of initial loading doses followed by maintenance doses every 4 or 8 weeks, depending on the patient's weight and the specific trial protocol.
  • What are the primary outcomes being measured in Ravulizumab clinical trials? The primary outcomes vary depending on the condition being studied. They often include measures of drug safety, such as the number of treatment-emergent adverse events, as well as efficacy measures like changes in disease-specific scores, relapse rates, and improvements in organ function. Pharmacokinetic and pharmacodynamic parameters are also frequently assessed.
  • Are there any studies looking at Ravulizumab in pediatric patients? Yes, there are clinical trials studying Ravulizumab in pediatric patients. For example, there is a study evaluating its use in children and adolescents with NMOSD, and another study in pediatric patients with generalized myasthenia gravis (gMG).
  • What is the mechanism of action of Ravulizumab? Ravulizumab is a monoclonal antibody that targets and inhibits the complement protein C5. By blocking C5, it prevents the formation of the membrane attack complex and reduces inflammation and cell damage associated with complement activation. This mechanism is believed to be beneficial in various autoimmune and inflammatory conditions.

Ongoing Clinical Trials on Ravulizumab

  • Study of Ravulizumab to Prevent Delayed Graft Function in Adult Patients After Kidney Transplant

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia France Germany Italy Poland +2

  • Study on Ravulizumab for Children with IgA Nephropathy (Ages 2-17)

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

  • Study on Optimizing Ravulizumab Dosing for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness and Safety of Ravulizumab for Children and Adolescents with Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study of KYV-101 Therapy for Patients with Refractory Generalized Myasthenia Gravis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Ravulizumab for Children Aged 6 to 17 with Generalized Myasthenia Gravis

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Italy The Netherlands Spain

  • Study on the Safety and Effectiveness of Pozelimab and Cemdisiran for Adults with Paroxysmal Nocturnal Hemoglobinuria Not Recently Treated with Complement Inhibitors

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Hungary Italy Poland Romania Spain

  • Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Italy The Netherlands +3

  • Study of Ravulizumab for Adults with Lupus Nephritis or IgA Nephropathy

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Poland Spain +1

  • Study on the Effectiveness and Safety of Ravulizumab for Adults with Corticosteroid-Resistant IgA Nephropathy Flares

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Neuromyelitis Optica Spectrum Disorder (NMOSD): A rare autoimmune disease that affects the central nervous system, primarily the optic nerves and spinal cord, causing inflammation and damage to these areas.
  • Paroxysmal Nocturnal Hemoglobinuria (PNH): A rare blood disorder characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function.
  • Generalized Myasthenia Gravis (gMG): An autoimmune neuromuscular disorder causing muscle weakness and fatigue, affecting multiple muscle groups throughout the body.
  • Complement System: A part of the immune system that enhances the ability of antibodies and immune cells to clear microbes and damaged cells, promote inflammation, and attack the cell membrane of pathogens.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. They are used to treat various diseases, including some types of cancer.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and the relationship between drug concentration and effect.
  • Bioavailability: The proportion of a drug or other substance which enters the circulation when introduced into the body and so is able to have an active effect.
  • Thrombotic Microangiopathy: A group of disorders characterized by blood clots in small blood vessels throughout the body, which can lead to organ damage.
  • Acute Kidney Injury: A sudden episode of kidney failure or kidney damage that happens within a few hours or days, causing waste products to build up in the blood.

References

  1. https://clinicaltrials.gov/study/NCT05346354
  2. https://clinicaltrials.gov/study/NCT06578949
  3. https://clinicaltrials.gov/study/NCT05288829
  4. https://clinicaltrials.gov/study/NCT04570397
  5. https://clinicaltrials.eu/trial/study-on-ravulizumab-for-children-aged-6-to-17-with-generalized-myasthenia-gravis/
  6. https://clinicaltrials.gov/study/NCT05288816
  7. https://clinicaltrials.gov/study/NCT06398158